Hikma Pharmaceuticals Share Discussion Threads

[mrthomas] 31/5/2016 11:29

as I said before surprised how few comments I made over 25% in just under 3 months am hoping it get back to top 100 and this could be a long term hold.
My daughter worked for them three months in Jordan and did not like them at all but as an investment they doing well

[r ball] 31/5/2016 10:09

What no comments?

[r ball] 17/5/2016 06:26

in line update. trend continues. £25

[r ball] 12/5/2016 09:26

excellent news. I would hate them the over promise.

[broadwood] 12/5/2016 07:20

Hikma reiterates guidance

[mrthomas] 22/4/2016 17:37

Am surprised how few post for this share but again today up even when market down a lot. This year is going to be an interesting ride next few months as if reach 26 not sure what to do hold for the long term or take the gains as already nearly 30% up

[r ball] 21/4/2016 17:48

30 days of straight gains?? topslice??

[r ball] 16/4/2016 19:47

Roxane acquisition and boehringer seat on the board.

[ali47fish] 16/4/2016 18:35

come on don,t leave me in the dark what's a boeringer synergy

[r ball] 16/4/2016 17:41

is it my boehringer synergy??

[ali47fish] 16/4/2016 12:43

the rise is because the directors have been buying and i think as a bid target when dfizer had to abandon the bid for allergan because of new rules in Us about taxation. i am still watching it to add more

[r ball] 16/4/2016 11:57

why the rise? now not ftse 100?

[broadwood] 11/4/2016 09:48

It has a compelling growth story.

Continuing towards those highs.

[r ball] 10/4/2016 20:42

ftse100 is kiss of death. would performance improve once m East settles down. thinking of buying chg to counter risk

[mrthomas] 08/4/2016 10:37

Held this share for just over a month and its been a real roller coaster. But having said that it could be a long term hold less see. Think that it could end up in the FTS 100 again at the end of this quarter in June that being the case the price will go up even higher.

management buying at that level is a good sign as well

[broadwood] 08/4/2016 09:05

Hikma Pharmaceuticals said on Friday that its abbreviated new drug application for fluticasone propionate and salmeterol inhalation powder has been accepted for filing by the Food and Drug Administration in the US.
The product is the generic version of GlaxoSmithKline's Advair Diskus, which is indicated for the treatment of asthma and the maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).

It is delivered using Vectura's proprietary dry powder inhaler and formulation technology.

Chief executive officer Said Darwazah said: "We are very pleased to have achieved this important milestone in the development of generic Advair Diskus. With our partner, Vectura, our team has worked closely with the FDA to ensure the quality of the ANDA submission.

"Our interactions with the FDA have helped clarify the requirements for the development of a robust, patient friendly, (AB-rated) substitutable generic product for Advair Diskus. We look forward to bringing to market this very important product for patients."

[broadwood] 08/4/2016 07:18

Great news.

Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, today confirms that its abbreviated new drug application (ANDA) for fluticasone propionate and salmeterol inhalation powder has been accepted for filing by the U.S. Food and Drug Administration (

[arja] 07/4/2016 16:09

what prompted the big turnaround today and like a one day reversal in charting terminology ? Ok,Dow falling and a bad market but it ignored that the other day ! R ball - that pullback did happen today !

[broadwood] 06/4/2016 10:14

That's a pretty big commitment in anyones book. Share price continues to recover and this news certainly helps.

[broadwood] 05/4/2016 18:39

The chairman and chief executive of Hikma Pharmaceuticals has purchased more than £600,000 worth of shares in the drugmaker.
Said Darwazah bought 30,000 shares for 2,055.00p each, totalling £616,499.98

JP Morgan on Wednesday reiterated its 'overweight' rating on the stock and set a target price of 2,300p, saying it believes there is a possible 13.5% upside from the opening price of 2,027p

[r ball] 05/4/2016 16:09

If you wait for a pullback it never happens. buy and strength and increase holding as share price rises.

[arja] 05/4/2016 12:23

amazing how some stocks such as this one powers ahead onn a rally bad day in market and with dow futures falling . Just wish I had some but maybe still time on a pullback ! Good luck to those holding stock or a long open position .

[3rd eye] 17/3/2016 10:24

Oh indeed, indeed.